Mercury Pharma Group Limited
Manufacture of basic pharmaceutical products · London
ActiveUnited KingdomIncorporated 1988Private Limited Company
Financial position
Accounts to 2025-12-31 · GBP · Company accounts
Net assets
£1,094,776,000
Cash
£1,666,000
Turnover
£229,682,000
Profit / loss
−£59,220,000
Current assets
£82,952,000
Creditors < 1 year
£143,569,000
Equity
£1,094,776,000
Average employees
111
Balance-sheet trend
GBP · companyFinancial statements
Selected figures from the best-ranked available filing for each period. Missing values remain unknown.
Some figures were read by AI from scanned accounts, so small errors are possible. View the filed accounts
| Reported figures | 2025-12-31Company · AI-read | 2024-12-31Company · AI-read |
|---|---|---|
| Balance sheet | ||
| Net assets | £1,094,776,000 | £1,153,996,000 |
| Equity | £1,094,776,000 | £1,153,996,000 |
| Share capital | £737,791,000 | £737,791,000 |
| Retained earnings | £126,380,000 | £185,600,000 |
| Assets | ||
| Fixed assets | £1,155,393,000 | £1,072,716,000 |
| Intangible assets | £1,019,492,000 | £870,270,000 |
| Investments | £135,901,000 | £202,446,000 |
| Current assets | £82,952,000 | £297,076,000 |
| Cash at bank | £1,666,000 | £1,730,000 |
| Debtors | £81,286,000 | £295,346,000 |
| Liabilities | ||
| Creditors within one year | £143,569,000 | £168,851,000 |
| Provisions | — | £46,945,000 |
| Net current assets | −£60,617,000 | £128,225,000 |
| Profit & loss | ||
| Turnover | £229,682,000 | £282,881,000 |
| Administrative expenses | £237,906,000 | £327,117,000 |
| Other operating income | £1,708,000 | — |
| Operating profit | −£6,516,000 | −£44,236,000 |
| Profit before tax | −£56,309,000 | −£32,742,000 |
| Tax | £2,911,000 | −£11,047,000 |
| Profit / loss | −£59,220,000 | −£21,695,000 |
| People & pay | ||
| Average employees | 111 | 113 |
| Directors' remuneration | £1,583,000 | £1,583,000 |
| Energy & carbon | ||
| Energy use | 39,554 kWh | 31,045 kWh |
| Source evidence | View filing | View filing |
From the accounts
What the accounts for 2025-12-31 say about themselves, read by AI from the scanned filing.
- Principal activity
- The principal activities of the Company are the ownership, development and licensing of intellectual property and product rights for the Group. The Company also acts as the holding company for the operating and group services businesses.
- What it does
- ownership of intellectual property · development of intellectual property · licensing of product rights · holding company · group services (AI keywords)
- The year
- The directors are satisfied with the performance of the Company to date. There have been no changes to the principal activities through the year. The Company and the Group have continued to expand their portfolio through product acquisitions and licensing agreements.
- Auditor
- Grant Thornton
- Audit opinion
- Clean (unmodified)
- Immediate parent
- Advanz Pharma Corp. Limited
- Ultimate parent
- Nordic Capital
- Ultimate controlling party
- Nordic Capital
- Accounts
- FRS 101
- Approved
- 2026-07-09, signed by Melvin Ferry
Subsidiaries (4)
- Mercury Pharmaceuticals Limited · 100 % · United Kingdom · Marketing, and distribution of pharmaceutical and healthcare products
- Advanz Pharma Services (UK) Limited · 100 % · United Kingdom · Management Services
- Abcur AB · 100 % · Sweden · Marketing of pharmaceutical products
- Advanz Pharma Services (India) Private Limited · 0.01 % · India · Management Services
Turnover by segment (10)
- License fees: 229,611 (000s) (2025-12-31)
- Management income: 71 (000s) (2025-12-31)
- License fees: 282,805 (000s) (2024-12-31)
- Management income: 76 (000s) (2024-12-31)
- Ireland: 229,623 (000s) (2025-12-31)
- United Kingdom: 12 (000s) (2025-12-31)
- Rest of the world: 47 (000s) (2025-12-31)
- Ireland: 253,954 (000s) (2024-12-31)
- United Kingdom: 28,879 (000s) (2024-12-31)
- Rest of the world: 48 (000s) (2024-12-31)
Acquisitions (3)
- Testoviron® (testosterone enantate) marketing authorisations, trademarks and distribution and other commercial know-how · 2025-06-16
- Zavesca® global rights · 2025-12-04
- Progynova® and Cyclo-Progynova® territory rights in the EMEA countries (excluding the Netherlands) · 2025-12-10
Share classes (2)
- 6,047,590,985 ordinary shares of £0.05 each of £0.05
- 2,827,094,510 ordinary shares of $0.05 each of $0.05
Events after the year end (2)
- On 18 February 2026, the Company entered into an agreement with Dr Reddy’s Laboratories Limited for the sale of its marketing rights relating to Progynova® in the India region for a total consideration of US$32.2 million, which was received by the Company on 20 February 2026.
- Subsequent to the year-end, geopolitical developments arising from the ongoing conflict in the Middle East have been observed. The Directors have assessed the potential impact of these developments and concluded that they do not have a material impact on the Company’s operations or financial position.
Contingent liabilities (1)
- The potential economic outflow of follow-on claims in relation to Liothyronine cannot be estimated reliably; accordingly, no additional provisions have been recognised.
Secured borrowing
Registered charges, lenders and security interests.
Charges and related records
8 outstanding chargesFixed · created 2026-06-16
—
OutstandingFixed · created 2025-05-21
—
OutstandingFixed · created 2025-05-21
—
OutstandingFixed · created 2024-08-27
—
OutstandingFixed · created 2023-07-20
—
OutstandingFixed · created 2023-07-20
—
OutstandingFixed · created 2021-08-05
—
OutstandingFixed · created 2021-08-05
—
OutstandingShow 33 satisfied / released
Fixed · created 2020-09-30 · satisfied 2021-06-02
—
SatisfiedFixed · created 2020-05-28 · satisfied 2021-06-02
—
SatisfiedFixed · created 2019-08-30 · satisfied 2021-06-02
—
SatisfiedFixed · created 2018-09-06 · satisfied 2021-06-02
—
SatisfiedFixed · created 2018-09-06 · satisfied 2021-06-02
—
SatisfiedFixed · created 2018-09-06 · satisfied 2021-06-02
—
SatisfiedFixed · created 2018-09-06 · satisfied 2021-06-02
—
SatisfiedFixed · created 2018-09-06 · satisfied 2021-06-02
—
SatisfiedAll Assets · created 2018-09-06 · satisfied 2021-06-02
—
SatisfiedFixed · created 2018-09-06 · satisfied 2021-06-02
—
SatisfiedFixed · created 2016-10-28 · satisfied 2018-09-14
—
SatisfiedFixed · created 2016-10-28 · satisfied 2018-09-14
—
SatisfiedFixed · created 2016-10-28 · satisfied 2018-09-14
—
SatisfiedFixed · created 2016-10-28 · satisfied 2018-09-14
—
SatisfiedFixed · created 2016-10-28 · satisfied 2018-09-14
—
SatisfiedFixed · created 2016-10-28 · satisfied 2018-09-14
—
SatisfiedFloating · created 2016-10-28 · satisfied 2018-09-14
—
SatisfiedFixed · created 2015-12-18 · satisfied 2018-09-14
—
SatisfiedFixed · created 2015-12-18 · satisfied 2018-09-14
—
SatisfiedFixed · created 2015-12-18 · satisfied 2018-09-14
—
SatisfiedFixed · created 2015-12-18 · satisfied 2018-09-14
—
SatisfiedFixed · created 2015-12-18 · satisfied 2018-09-14
—
SatisfiedFixed · created 2015-12-18 · satisfied 2018-09-14
—
SatisfiedFixed · created 2015-12-18 · satisfied 2018-09-14
—
SatisfiedAll Assets · created 2012-12-21 · satisfied 2015-11-02
All monies
SatisfiedFixed · created 2012-12-21 · satisfied 2015-11-02
All monies
SatisfiedAll Assets · created 2012-10-30 · satisfied 2015-11-02
All monies
SatisfiedFixed · created 2012-10-30 · satisfied 2015-11-02
All monies
SatisfiedShares · created 2010-03-19 · satisfied 2012-10-17
All monies
SatisfiedAll Assets · created 2010-01-20 · satisfied 2012-10-17
All monies
SatisfiedUnknown · created 1995-08-02 · satisfied 2009-09-05
All monies
SatisfiedProperty · created 1994-02-16 · satisfied 2009-09-05
All monies
SatisfiedIntellectual Property · created 1992-10-23 · satisfied 1995-07-01
£500,000 DUE FROM THE COMPANY TO THE CHA RGEE
Satisfied